U.S. Other Utilities Stock News

NYSE:KNX
NYSE:KNXTransportation

Knight-Swift (KNX) Valuation Check After Fourth Quarter Loss And Earnings Slowdown

Knight-Swift Transportation Holdings (KNX) just posted its fourth quarter 2025 results, reporting revenue of US$1,856.33 million and a net loss of US$6.8 million, compared with net income of US$69.5 million in the same period a year earlier. See our latest analysis for Knight-Swift Transportation Holdings. The weak fourth quarter and swing to a net loss sit against a share price of US$55.10, with a 90 day share price return of 23.02% and a 5 year total shareholder return of 39.16%. This...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Did RMC-5127’s First-in-Human Trial Launch Just Shift Revolution Medicines' (RVMD) Investment Narrative?

Revolution Medicines recently dosed the first patient in its first-in-human trial of RMC-5127, an open-label study assessing safety, tolerability, pharmacokinetics and early antitumor activity in RAS G12V-mutated solid tumors after standard therapies have failed. The program targets RAS G12V, the second most common driver of RAS-addicted cancers in the US, affecting roughly 48,000 patients annually across pancreatic, colorectal and non-small cell lung cancers. We’ll now examine how the...
NYSE:AGRO
NYSE:AGROFood

The Bull Case For Adecoagro (AGRO) Could Change Following Upgraded Earnings Outlook And Value Rating Shift

In recent months, Adecoagro has received a Zacks Rank #2 (Buy) as analysts sharply revised full-year earnings estimates higher and highlighted its value rating. What stands out is that Adecoagro’s valuation metrics, including P/E, PEG, P/B, and P/S ratios, compare favorably with its industry even as earnings expectations improve. We’ll now examine how this stronger earnings outlook, combined with favorable valuation ratios, shapes Adecoagro’s broader investment narrative for investors...
NasdaqGM:TRVI
NasdaqGM:TRVIPharmaceuticals

Did JAMA-Published CORAL Data on Nalbuphine ER Just Shift Trevi Therapeutics' (TRVI) Investment Narrative?

Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis were published in the Journal of the American Medical Association, with safety outcomes broadly consistent with prior studies. The data showed similar discontinuation rates between nalbuphine ER and placebo and fewer serious adverse events in the nalbuphine ER group, underscoring a potentially differentiated safety profile. Next, we’ll...
NYSE:UWMC
NYSE:UWMCDiversified Financial

Does UWM Holdings' (UWMC) CEO Stock Sale Reframe the Market’s View of Management Alignment?

In January 2026, UWM Holdings CEO Mat Ishbia indirectly sold 1,898,622 shares of Class A common stock for about US$11.14 million under a pre-arranged 10b5-1 trading plan, reducing his overall holdings while leaving his direct ownership unchanged. The scale and timing of these insider sales, against a backdrop of weak mortgage loan volumes, have intensified investor focus on UWM’s leadership intentions and longer-term corporate direction. We’ll now examine how Ishbia’s sizable insider sale...
NYSE:SPH
NYSE:SPHGas Utilities

Assessing Suburban Propane Partners (SPH) Valuation After Mixed Recent Returns And Conflicting Fair Value Views

What recent performance says about Suburban Propane Partners Suburban Propane Partners (SPH) has seen mixed share performance recently, with a 1-day return of about a 1% decline contrasted against gains over the past week, month, and past 3 months. See our latest analysis for Suburban Propane Partners. That recent 1 day share price pullback sits against a 30 day share price return of 7.92% and a 90 day gain of 12.12%, while the 5 year total shareholder return of 91.12% shows how different the...
NYSE:CNS
NYSE:CNSCapital Markets

The Bull Case For Cohen & Steers (CNS) Could Change Following Margin Squeeze Despite Rising Revenue

Cohen & Steers, Inc. reported past fourth-quarter 2025 results, with revenue rising to US$143.8 million from US$139.78 million a year earlier, while net income declined to US$34.88 million from US$45.82 million and diluted EPS from continuing operations eased to US$0.68 from US$0.89. This combination of higher revenue but lower profitability highlights shifting cost or business mix pressures that may be important for understanding the firm’s earnings quality. We will now examine how this mix...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after reporting full year 2025 earnings, moving from a prior net loss to US$1.4b in net income on US$17.3b in sales. See our latest analysis for Teva Pharmaceutical Industries. The recent earnings beat and return to profitability have gone hand in hand with a strong share price run, with a 90 day share price return of 66.57% and a 1 year total shareholder return of 96.43% suggesting momentum has been building over both...
NasdaqGS:EXPO
NasdaqGS:EXPOProfessional Services

A Look At Exponent (EXPO) Valuation As Earnings Optimism Builds Before February 5 Report

Exponent (EXPO) heads into its February 5 earnings report with analysts expecting higher revenue and a year over year earnings increase, and the Most Accurate Estimate sitting above the broader consensus. See our latest analysis for Exponent. Exponent’s share price has recently been choppy, with a 7 day share price return of a 4.6% decline, a 30 day share price return of 2.5%, and a current price of US$71.87. Its 1 year total shareholder return shows a 20.5% decline, which points to weaker...
NasdaqGS:TTMI
NasdaqGS:TTMIElectronic

How Raytheon’s LTAMDS Supply Deal And Index Shift At TTM Technologies (TTMI) Has Changed Its Investment Story

In late January 2026, Raytheon announced a multi-year agreement with TTM Technologies worth up to US$200 million over three years to supply radio frequency assemblies, electronic hardware and printed circuit boards for its Lower Tier Air and Missile Defense Sensor program. The deal, alongside TTM’s move from the S&P SmallCap 600 to the S&P MidCap 400, highlights the company’s growing role in defense electronics and its rising profile among mid-cap index investors. With this expanded Raytheon...
NYSE:VMI
NYSE:VMIConstruction

Valmont Industries (VMI) Valuation Check After Earnings Surprises And Upbeat Analyst Revisions

Valmont Industries (VMI) is back on many investors’ screens after a run of positive earnings surprises and upward earnings estimate revisions, a combination that has coincided with a recent 52 week high. See our latest analysis for Valmont Industries. The recent 30 day share price return of 8.22% and a 1 year total shareholder return of 38.40% suggest momentum has been building, even after a small 1 day pullback and a modest 90 day share price gain of 9.75%. If you are looking beyond...
NYSE:UAN
NYSE:UANChemicals

Did CVR Partners’ (UAN) Q4 Loss Outlook and 2025 Profit Guidance Just Reframe Its Earnings Story?

In late January 2026, CVR Partners, LP issued earnings guidance for the Fourth Quarter and full-year 2025, estimating a Q4 net loss of US$7 million to US$14 million and full-year net income of US$95 million to US$102 million. The contrast between an expected quarterly loss and a profitable full year highlights the company’s uneven earnings profile and potential seasonality in its results. We will now consider how CVR Partners’ expectation of a Q4 loss alongside full-year profitability shapes...